XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.25.2

Commitments and Contingencies | 6 Months Ended
--- | ---
Jun. 30, 2025
Commitments and Contingencies Disclosure [Abstract] |
Commitments and Contingencies | Commitments and Contingencies Leases We lease our facilities in Emeryville, California and Düsseldorf, Germany. We lease and sublease certain manufacturing and office space with lease terms ranging from 3 to 12 years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include options to renew or extend the lease for two successive five-year terms. These optional periods have not been considered in the determination of the right-of-use assets or lease liabilities associated with these leases as we did not consider the exercise of these options to be reasonably certain. Our lease-related amounts are presented below (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Operating lease expense | $ | 1,436 |  |  | $ | 1,496 |  |  | $ | 2,863 |  |  | $ | 2,912 |
Cash paid for lease liabilities (1) | $ | 1,803 |  |  | $ | 1,904 |  |  | $ | 3,660 |  |  | $ | 3,778 |
Sublease income (2) | $ | 2,226 |  |  | $ | 2,205 |  |  | $ | 4,452 |  |  | $ | 603 |
(1)Cash paid for amounts included in the measurement of lease liabilities is included in change in lease liabilities in our condensed consolidated statement of cash flows. (2)Sublease income is included net within “Other income (expense)” in our condensed consolidated statements of operations. Rent received from our subtenant in excess of rent paid to the landlord is shared by paying the landlord 50% of the excess rent. The excess rent is considered a variable lease payment and the total estimated payments are being recognized as additional rent expense on a straight-line basis. The balance sheet classification of our operating lease liabilities was as follows (in thousands):
| June 30, 2025 |  | December 31, 2024
Operating lease liabilities: |  |  |
Current portion of lease liabilities (included in other current liabilities) | $ | 4,067 |  |  | $ | 4,175 |
Long-term portion of lease liabilities | 24,726 |  |  | 26,388 |
Total operating lease liabilities | $ | 28,793 |  |  | $ | 30,563 |
As of June 30, 2025, the maturities of our sublease income and operating lease liabilities were as follows (in thousands):
Years ending December 31, | Sublease Income |  | Operating Lease Liabilities
2025 (remaining) | $ | 3,064 |  |  | $ | 3,658 |
2026 | 6,342 |  |  | 6,591 |
2027 | 6,564 |  |  | 6,535 |
2028 | 6,794 |  |  | 6,520 |
2029 | 7,031 |  |  | 6,423 |
Thereafter | 9,160 |  |  | 8,760 |
Total | $ | 38,955 |  |  | 38,487 |
Less: |  |  |
Present value adjustment |  |  | (9,694) |
Total |  |  | $ | 28,793 |
The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liabilities were as follows:
| June 30, 2025 |  | December 31, 2024
Weighted average remaining lease term | 5.3 years |  | 5.9 years
Weighted average discount rate | 9.5 | % |  | 10.1 | %
Commitments We have entered into material purchase commitments with commercial manufacturers for the supply of HEPLISAV-B. As of June 30, 2025, our material non-cancelable purchase and other commitments for the supply of HEPLISAV-B totaled $79.1 million, which are expected to be paid through 2029. In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition, in the normal course of operations, we have entered into license and other agreements and intend to continue to seek additional rights relating to compounds or technologies in connection with our discovery, manufacturing and development programs. Under the terms of the agreements, we may be required to pay future up-front fees, milestones and royalties on net sales of products originating from the licensed technologies, if any, or other payments contingent upon the occurrence of future events that cannot reasonably be estimated. We also rely on and have entered into agreements with research institutions, contract research organizations and clinical investigators as well as clinical material manufacturers. These agreements are terminable by us upon written notice. Generally, we are liable only for actual effort expended by the organizations at any point in time during the contract through the notice period. Contingencies From time to time, we may be involved in claims, suits, and proceedings arising from the ordinary course of our business, including actions with respect to intellectual property claims, commercial claims, and other matters. Such claims, suits, and proceedings are inherently uncertain and their results cannot be predicted with certainty. Regardless of the outcome, such legal proceedings can have an adverse impact on us because of legal costs, diversion of management resources, and other factors. In addition, it is possible that a resolution of one or more such proceedings could result in substantial damages, fines, penalties or orders requiring a change in our business practices, which could in the future materially and adversely affect our financial position, results of operations, or cash flows in a particular period.

X
- References No definition available. + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for commitments and contingencies. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration